Ladarixin Sodium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go

Report scope. This 2026 Drug Asset Due Diligence Report evaluates Ladarixin Sodium as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.

Executive recommendation: CONDITIONAL GO

Ladarixin Sodium is a Small molecule drug associated with CXCR1 x CXCR2 and a global highest development stage of Phase 2. The lead disclosed indication is Obesity. The current evidence supports a CONDITIONAL GO posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.

Decision memo

• Asset: Ladarixin Sodium
• Target: CXCR1 x CXCR2
• Lead indication: Obesity
• Highest phase: Phase 2
• Matched trials: 12
• Matched result records: 6
• Matched asset deals: 0

Use PatSnap Life Sciences MCP servers to validate the Ladarixin Sodium diligence evidence.

1. Asset identity and development status

The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For Ladarixin Sodium, the MCP profile identifies CXCR1 x CXCR2 as the primary target context and Obesity as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.

Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.

Use PatSnap Life Sciences MCP servers to validate the Ladarixin Sodium diligence evidence.

2. Clinical program: design and endpoint audit

The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.

Use PatSnap Life Sciences MCP servers to validate the Ladarixin Sodium diligence evidence.

3. Clinical readouts: what is known

Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess Effect and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With Recent Onset Type 1 Diabetes and Low Residual β-cell Function at Baseline (GLADIATOR)

Study: NCT04628481 (CTgov). Phase: Phase 2. Enrollment: 289. Published: 2026-08-31.

Change From Baseline in 2-hour Area Under the Concentration-time Curve (AUC) of C-peptide Response to the Mixed Model Tolerance Test (MMTT)(Mean) = -0.284 nanomole*hour/Liter (nmol*hr/L) (95%CI, -0.453 to -0.114) | Change From Baseline in 2-hour Area Under the Concentration-time Curve (AUC) of C-peptide Response to the Mixed Model Tolerance Test (MMTT)(Mean) = -0.151 nanomole*hour/Liter (nmol*hr/L) (95%CI, -0.373 to 0.071)

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes and Preserved Beta-cell Function at Baseline.

Study: NCT04899271 (CTgov). Phase: Phase 2. Enrollment: 25. Published: 2025-05-14.

Number of Patients With HbA1c <7% and Daily Insulin Requirement <0.50 IU/Kg/Day at Month 12 = 11 Pts | Number of Patients With HbA1c <7% and Daily Insulin Requirement <0.50 IU/Kg/Day at Month 12 = 5 Pts

Randomized, Placebo-controlled, Double-blinded, 2-parallel Arm, Clinical Trial Evaluating Ladarixin 400 mg Bid as Adjunctive Therapy to Improve Glycemic Control in Overweight Insulin-resistant Patients With Type 1 Diabetes.

Study: NCT05368402 (CONSERVA, CTgov). Phase: Phase 2. Enrollment: 3. Published: 2025-02-03.

Number of Participants With an HbA1c Reduction From Baseline of ≥0.50% (Absolute Difference) Without Episodes of Severe Hypoglycemia. = 0 Pts | Number of Participants With an HbA1c Reduction From Baseline of ≥0.50% (Absolute Difference) Without Episodes of Severe Hypoglycemia. = 0 Pts

<i>Post hoc</i> analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders.

Study: NCT02814838 (Pubmed | Front Endocrinol (Lausanne)). Phase: Phase 2. Enrollment: Not disclosed. Published: 2023-01-01.

C-peptide AUC (0-120 min) = 0.72 nmol/L (95%CI, 0.9 - 1.34)

A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes

Study: NCT02814838 (MEX0114, CTgov). Phase: Phase 2. Enrollment: 76. Published: 2021-01-12.

Area Under the Curve (AUC)(0-2 h) of C-peptide Response to the Mixed Meal Tolerance Test (MMTT) at Week 13(Mean) = 4.026 log(ng*hr/ml [0-2 h]+1) | Area Under the Curve (AUC)(0-2 h) of C-peptide Response to the Mixed Meal Tolerance Test (MMTT) at Week 13(Mean) = 3.886 log(ng*hr/ml [0-2 h]+1)

MiR-375 levels in newly diagnosed type 1 diabetes: results from a phase 2, multicentre, randomised, placebo controlled trial (MEX0114)

Study: NCT02814838 (MEX0114, EASD2020). Phase: Phase 2. Enrollment: 76. Published: 2020-09-24.

HbA1c = 76.6 % | HbA1c = 45.8 %

For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.

Use PatSnap Life Sciences MCP servers to validate the Ladarixin Sodium diligence evidence.

4. Market and competitive position

The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark Ladarixin Sodium against approved therapies and clinical competitors in Obesity, including likely standards of care at the expected launch date.

Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.

Use PatSnap Life Sciences MCP servers to validate the Ladarixin Sodium diligence evidence.

5. Transaction precedent and economics

Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.

6. IP and freedom-to-operate screen

Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.

The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.

Use PatSnap Life Sciences MCP servers to validate the Ladarixin Sodium diligence evidence.

7. Principal risks and diligence gates

1. Identity risk: resolve all aliases, formulations, combinations, and owners.
2. Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
3. Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
4. IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
5. CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
6. Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
7. Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.

8. Final go/no-go memorandum

CONDITIONAL GO

Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.

Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-15. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.